Study of 99mTc-Sestamibi SPECT/CT Imaging for the Preoperative Diagnosis of Renal Oncocytoma

Completed · Not applicable

Conditions studied: Clinical T1 Renal Mass

In brief

The objective of this study is to investigate the utility of 99mTc-sestamibi SPECT/CT imaging for the diagnosis of renal oncocytomas.

Key facts

Study ID

NCT02160925

Run by

Johns Hopkins University

People needed

125

Starts

2014-05-01

Expected to finish

2018-06-01

Last updated by the study team

2019-07-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Presence of a solid enhancing cT1 renal mass detected on cross-sectional imaging
• Scheduled to undergo surgery with either partial or radical nephrectomy
• Age ≥18 years

You may not qualify if…

• Pregnancy
• Evidence of nodal or distant metastases
• History of other malignancy with concern for renal metastasis
• Known allergy to technetium or sestamibi

Where it is running

• Johns Hopkins Hospital — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.